Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Journal title
Antimicrobial agents and chemotherapyDate Published
2000-05Publication Volume
44Publication Issue
5Publication Begin page
1409
Metadata
Show full item recordCitation
Hammerschlag MR, Roblin PM. Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrob Agents Chemother. 2000 May;44(5):1409. doi: 10.1128/AAC.44.5.1409-1409.2000. PMID: 10819727; PMCID: PMC89886.Collections
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
Related articles
- A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
- Authors: File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A
- Issue date: 1997 Sep
- Levofloxacin in the treatment of community acquired pneumonia.
- Authors: File TM Jr
- Issue date: 1999 Jan-Feb
- Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
- Authors: Hammerschlag MR, Roblin PM
- Issue date: 2000 Jul
- The use of levofloxacin in the treatment of respiratory tract infection.
- Authors: Shah PM
- Issue date: 2000 Oct
- [Chlamydia pneumoniae and other Chlamydia species in community-acquired pneumonia].
- Authors: Ruiz Carmona M, Soler Polcar N, Torres Martí A
- Issue date: 1998 Sep